Antiarrhythmic therapy in patients with congestive heart failure

Preview

Patients with congestive heart failure plus ventricular arrhythmias are at risk for sudden death. Whether suppression of these arrhythmias improves mortality rates is unclear. The type of cardiomyopathy (ie, ischemic or nonischemic) and the presence or absence of symptoms influence the diagnostic and therapeutic options, but in defined subpopulations, antiarrhythmic therapy is clearly indicated. The authors describe these subpopulations and discuss ongoing cardiovascular research.

Additional information

Notes on contributors

Jamie B. Conti

Jamie B. Conti, MD Dr Conti (right) is a research fellow, American Heart Association, Florida affiliate, and an instructor of medicine, division of cardiovascular medicine, University of Florida College of Medicine, Gainesville.

Anne B. Curtis

Anne B. Curtis, MD Dr Curtis (left) is associate professor of medicine and director of clinical electrophysiology, division of cardiovascular medicine, University of Florida College of Medicine.